Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach

Br J Haematol. 2016 Aug;174(3):473-7. doi: 10.1111/bjh.13776. Epub 2015 Oct 12.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1 / immunology*
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Female
  • Humans
  • Male
  • Membrane Glycoproteins / immunology*
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Salvage Therapy / methods*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Membrane Glycoproteins
  • daratumumab
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1